Rapamycin in dogs: the evidence
What the aging-research databases and the canine literature hold for Rapamycin (names searched: Rapamycin, sirolimus). Compiled from DrugAge, the canine aging corpus and FDA CVM FOI summaries; nothing here is inferred.
Lifespan experiments in other species (DrugAge)
37 experiments recorded, by species: Mus musculus 24, Caenorhabditis elegans 8, Drosophila melanogaster 5.
NIA Interventions Testing Program rows
| Species | Strain | Dose | Age at start | Duration | Sex | Mean lifespan Δ% | Mean sig. | Max lifespan Δ% | Max sig. | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| Mus musculus | UM-HET3 | 14 ppm food (2.24 ppm/day bodyweight) | 20 months | until death | Female | 13 | S | 14 | S | PMID 19587680 |
| Mus musculus | UM-HET3 | 14 ppm food (2.24 ppm/day bodyweight) | 20 months | until death | Male | 9 | S | 9 | S | PMID 19587680 |
| Mus musculus | UM-HET3 | 14 ppm food (2.24 ppm/day bodyweight) | 9 months | until death | Female | 18 | S | 13 | S | PMID 20974732 |
| Mus musculus | UM-HET3 | 14 ppm food (2.24 ppm/day bodyweight) | 9 months | until death | Male | 10 | S | 16 | S | PMID 20974732 |
| Mus musculus | UM-HET3 | 42 ppm food | 9 months | until death | Female | 26 | S | 11 | S | PMID 24341993 |
| Mus musculus | UM-HET3 | 42 ppm food | 9 months | until death | Male | 23 | S | 8 | S | PMID 24341993 |
| Mus musculus | UM-HET3 | 14 ppm food | 9 months | until death | Female | 21 | S | 11 | S | PMID 24341993 |
| Mus musculus | UM-HET3 | 14 ppm food | 9 months | until death | Male | 13 | S | 8 | S | PMID 24341993 |
| Mus musculus | UM-HET3 | 4.7 ppm food | 9 months | until death | Female | 16 | S | 5 | S | PMID 24341993 |
| Mus musculus | UM-HET3 | 4.7 ppm food | 9 months | until death | Male | 3 | NS | 6 | NS | PMID 24341993 |
| Mus musculus | UM-HET3 | 42 ppm food | 20 months | 3 months | Female | 4 | NS | 4 | NS | PMID 33145977 |
| Mus musculus | UM-HET3 | 42 ppm food | 20 months | 3 months | Male | 11 | S | 5 | NS | PMID 33145977 |
| Mus musculus | UM-HET3 | 42 ppm food every other month | 20 months | unti death | Female | 8 | S | 10 | S | PMID 33145977 |
| Mus musculus | UM-HET3 | 42 ppm food every other month | 20 months | unti death | Male | 9 | S | 9 | S | PMID 33145977 |
| Mus musculus | UM-HET3 | 42 ppm food | 20 months | unti death | Female | 15 | S | 12 | S | PMID 33145977 |
| Mus musculus | UM-HET3 | 42 ppm food | 20 months | unti death | Male | 11 | S | 9 | S | PMID 33145977 |
Other DrugAge rows (sample)
| Species | Strain | Dose | Age at start | Duration | Sex | Mean lifespan Δ% | Mean sig. | Max lifespan Δ% | Max sig. | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | N2 | 100 µM | Unknown | 19 | S | NA | PMID 22560223 | |||
| Caenorhabditis elegans | N2 | 1 nM | Unknown | 16.2 | S | NA | PMID 23698443 | |||
| Caenorhabditis elegans | N2 | 1 nM | Unknown | 20.6 | S | NA | PMID 23698443 | |||
| Caenorhabditis elegans | N2 | 100 µM | Unknown | 26 | S | 34.84 | NA | PMID 24332851 | ||
| Caenorhabditis elegans | N2 | 10 µM | Unknown | 18.9 | S | NA | PMID 26676933 | |||
| Caenorhabditis elegans | N2 | 100 µM | Unknown | 21.3 | S | NA | PMID 29874838 | |||
| Caenorhabditis elegans | N2 | 100 µM | Unknown | 25.9 | S | 16.38 | NA | PMID 30269951 | ||
| Caenorhabditis elegans | N2 | 50 µM | Unknown | 14.14 | S | NA | PMID 30970250 | |||
| Drosophila melanogaster | white Dahomey | 200 µM | Female | 13 | S | NA | PMID 20074526 | |||
| Drosophila melanogaster | Dahomey | 10 µM | Unknown | 12.98 | S | -2.89 | NA | PMID 28025308 | ||
| Drosophila melanogaster | Dahomey | 5 µM | Unknown | 16.35 | S | -2.89 | NA | PMID 28025308 | ||
| Drosophila melanogaster | Oregon-R | 100 µM | Male | 38.4 | S | 50 | NA | PMID 30269951 | ||
| Drosophila melanogaster | Canton-S | 20 μM | Female | 4.29 | NS | NA | PMID 33008901 | |||
| Mus musculus | 129/Sv | 1.5 ppm bodyweight subcutaneous injection 3 times a week for 2 weeks followed by a 2-week break | 2 months | until death | Female | 10 | NS | 8 | S | PMID 22107964 |
Lifespan experiments in dogs (DrugAge)
DrugAge records no dog lifespan experiment for this compound.
Dog-equivalent doses (allometric starting points, not recommendations)
Method: FDA 2005 Km body-surface-area conversion; starting-point heuristic only.
No mg/kg dose in DrugAge to translate (doses reported as ppm of diet or a concentration).
Canine aging literature (Europe PMC corpus)
152 corpus records mention this compound.
Records matching randomized or placebo-controlled trial vocabulary
- Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project. (GeroScience, 2025). PMID 39951177
…The Test of Rapamycin In Aging Dogs (TRIAD) randomized clinical trial is a parallel-group, double-masked, randomized, placebo-controlled, multicenter trial that will… - A masked, placebo-controlled, randomized clinical trial evaluating safety and the effect on cardiac function of low-dose rapamycin in 17 healthy client-owned dogs. (Frontiers in veterinary science, 2023). PMID 37275618
…included in a prospective, randomized, placebo-controlled, masked clinical trial. Low-dose rapamycin (0.025 mg/kg) or placebo was administered three times per… - A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs. (GeroScience, 2017). PMID 28374166
…placebo or a non-immunosuppressive dose of rapamycin for 10 weeks. All dogs received clinical and hematological exams before, during, and after the trial… - Canine prostate cancer cell transcriptome reveals important dysregulation in PI3K/AKT/mTOR pathway. (Journal of comparative pathology, 2025). PMID 40328211
…Considering the central role of mammalian target of rapamycin (mTOR) in carcinogenesis, the use of rapamycin, an mTOR inhibitor, has attracted considerable attention. In… - Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. (Transplantation, 1991). PMID 1871787
…These preclinical findings compel careful Phase I trials, in order to assess the safety and synergistic efficacy of RAPA in combination drug regimens with…
Top hits in the core tier
- A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs. (GeroScience, 2017). PMID 28374166
- Rapamycin as a potential intervention to promote longevity and extend healthspan in companion dogs (Journal of veterinary science, 2025).
- Rapamycin: Risking Harm for Canine Longevity. (The American journal of bioethics : AJOB, 2018). PMID 30339072
- Next Generation Strategies for Geroprotection via mTORC1 Inhibition. (The journals of gerontology. Series A, Biological sciences and medical sciences, 2020). PMID 30794726
- Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project. (GeroScience, 2025). PMID 39951177
- Effects of metformin, rapamycin, and resveratrol on cellular metabolism of canine primary fibroblast cells isolated from large and small breeds as they age. (GeroScience, 2021). PMID 33733399
- Research to Promote Longevity and Health Span in Companion Dogs: A Pediatric Perspective. (The American journal of bioethics : AJOB, 2018). PMID 30339074
- Pet dogs set to test anti-ageing drug. (Nature, 2014). PMID 25355339
- Translational Geroscience: Targeting mTOR Signaling to Promote Healthy Longevity (Innovation in aging, 2017).
- Case report: Severe asymptomatic hypertriglyceridemia associated with long-term low-dose rapamycin administration in a healthy middle-aged Labrador retriever. (Frontiers in veterinary science, 2023). PMID 38094495
- A masked, placebo-controlled, randomized clinical trial evaluating safety and the effect on cardiac function of low-dose rapamycin in 17 healthy client-owned dogs. (Frontiers in veterinary science, 2023). PMID 37275618
- SEX AND TISSUE SPECIFIC ROLES OF MTORC2 IN HEALTHSPAN, METABOLISM, AND SURVIVAL (Innovation in aging, 2019).
- New tricks from old dogs join the fight against ageing. (Nature, 2017). PMID 29239380
- Sex-dimorphic immune trajectories across the canine lifespan and early-life signatures of geroprotective interventions (, 2026). doi:10.64898/2026.09.09.750505
- The companion dog as a unique translational model for aging. (Seminars in cell & developmental biology, 2017). PMID 28803893
FDA CVM FOI summaries for dog products
No FDA FOI summary for a dog product contains this ingredient (it is not a marketed veterinary product).
Evidence gaps reported by the dossier tool
- DrugAge has no dog lifespan experiment for this compound.
- No mg/kg animal dose in DrugAge to translate (doses reported as ppm or % of diet).
- No FDA FOI summary for a dog product containing this ingredient.
Reproduce: intervention_dossier(compound="Rapamycin") in dog-geroscience-mcp.